Wockhardt’s Q4 FY23 three fold jump in EBITDA over Q4 FY22

Two patents were filed during the quarter ended 31st March, 2023 and the cumulative filings till date are 3239

Sun Pharmaceutical Industries posts Q4 FY23 consolidated PAT at Rs. 2016.78 Cr

The company has reported total income of Rs. 11303.95 crores during the period ended March 31, 2023

Top management changes at IOL Chemicals and Pharmaceuticals

Vikas Vij has been appointed as Chief Executive Officer (CEO) of the company

CTSI appoints Harish Trivedi as CEO, South Asia

Dr. Reddy's divests non-core brands in dermatology to Eris Lifesciences for Rs 275 Cr

Eris Lifesciences will be assigned the trademark of these brands by Dr. Reddy's for a consideration of Rs. 275 crore

Thyrocare adopts SigTuple’s AI100 to make quality diagnostics accessible

In a bid to better leverage its clinical expertise and drive quality reporting across its centres, Thyrocare has added SigTuple’s AI100 to automate the microscopic review in its laboratories

Pfizer appoints Meenakshi Nevatia as MD and Additional Director

She is a seasoned leader with nearly 30 years of business leadership and consulting experience with top companies such as Mckinsey and Co, Novartis Pharmaceuticals and Stryker India Pvt. Ltd.

Dr. Reddy’s included in Bloomberg Gender-Equality Index for 6th year in a row

The company has also been named among global sustainability leaders for the 7th year in a row in the Dow Jones Sustainability Index in the Emerging Markets category

Sun Pharma Q3 FY23 Gross Sales up 13.1%; Net profit up 5.2%

India formulation sales at Rs. 3,391.9 crore, up 7.1% over Q3 last year

Dr. Reddy’s completes clinical studies of its rituximab biosimilar for filing in the U.S., Europe

Following successful completion of full set of clinical studies of proposed rituximab biosimilar candidate DRL_RI, Dr. Reddy’s will now prepare to file in the United States, European Union and other regions